Health Care·Biotechnology·$3.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.07 | N/A | -4.48% |
management commentary, guidance changes, and full analysis available with Pro.
| -4.48% |
Tone: Cautiously Optimistic
Management expressed a cautious optimism about the company's future initiatives. They emphasized their commitment to growth despite the earnings miss.
We are focused on our strategic initiatives to drive growth.
Our team remains committed to delivering value to our stakeholders.
Catalyst Pharmaceuticals reported a loss per share that was slightly worse than expected, but the stock still rose by 0.63%. This increase may reflect investor confidence in the company's long-term strategy, despite the earnings miss. The lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TEVA PHARMACEUTICAL ADR
May 9, 2016